Zymeworks(US:ZYME)2022-01-12 21:23Company Overview - Zymeworks is developing multifunctional therapeutics through its proprietary platforms, leading the paradigm shift in drug development[4] - The company's lead asset, zanidatamab, is a bispecific antibody with the potential to become a new foundational HER2-targeted therapy[4] - Zymeworks' platforms enable the creation of tailor-made biotherapeutics with modular and scalable designs[12, 13] Partnership and Revenue - Zymeworks has received over $225 million in partnership revenue with more than $8.5 billion in total deal value[16] - Royalty percentages from partnerships range from low-mid single digits to tiered up to 20% for specific products and territories[16] Clinical Pipeline - Zanidatamab - Zanidatamab monotherapy in HER2-expressing late-line biliary tract cancer (BTC) showed a confirmed partial response (cPR) rate of 40% and a disease control rate (DCR) of 65%[33] - Zanidatamab plus chemotherapy in HER2+ first-line gastroesophageal adenocarcinoma (GEA) demonstrated a 93% confirmed objective response rate (cORR) for the proposed Phase 3 regimen[42] - Zanidatamab plus chemotherapy in HER2+ 3L+ breast cancer showed a confirmed objective response rate (cORR) of 36.4% and a disease control rate (DCR) of 86.4%[52] Clinical Pipeline - ZW49 - ZW49, a bispecific ADC for HER2-expressing cancers, has shown multiple confirmed responses and stable disease in several tumor types[27] - Phase 1 clinical data for ZW49 is expected to be reported at a medical meeting in 2022[30] Upcoming Milestones - Clinical data milestones for zanidatamab in 1L HER2+ GEA, 1L HER2+ breast cancer, and 3L+ HER2+ HR+ breast cancer are expected in the first half of 2022[54] - Phase 1 dose escalation and expansion cohorts for ZW49 are ongoing in 2022[54]